Evidence-based·Updated November 19, 2026·How we grade evidence

Akkermansia

ProbioticAkkermansia muciniphila

Small trials, mostly of pasteurized Akkermansia and mostly run by researchers linked to the companies that sell it, suggest modest improvements in insulin sensitivity and less weight regain after dieting. The largest trial missed its main goal, and benefits appear mainly in people with little Akkermansia to begin with.

Taking Akkermansia with other supplements or medications?Check your whole list for interactions. Free, no account.

Quick decision guide

May help most

Adults with overweight, prediabetes or metabolic syndrome who want to try an option with early evidence, alongside diet and medical care

Common dosing range

Studied doses of pasteurized Akkermansia: 10 billion cells per day for 3 months and 30 billion cells per day for 4 months; the dose in the 24-week weight-maintenance trial is not stated in its abstract

When to expect effects

3 to 6 months in trials

Watch out for

Live and pasteurized products are different; most evidence is for pasteurized; safety in pregnancy, breastfeeding and young children has not been established

What is it

Akkermansia muciniphila is a bacterium that normally lives in the mucus layer lining the human gut. It is sold as a supplement in two quite different forms. Pasteurized Akkermansia is heat-treated so the cells are no longer alive; the European Food Safety Authority's safety review of it required that viable cells be below the limit of detection (fewer than 10 per gram). Live Akkermansia contains living bacteria and is sold either on its own or in multi-strain products with other bacteria and fiber. The trials below used one form or the other, and a result for one form does not automatically apply to the other. In the EU, the European Food Safety Authority (EFSA) judged pasteurized Akkermansia safe as a novel food at up to 34 billion cells a day for adults, excluding pregnant and breastfeeding women (2021), and in 2025 for teenagers aged 12 to 17 at up to 21 billion cells a day (ages 12 to 13) or 30 billion (ages 14 to 17). The FDA's GRAS Notice Inventory (last updated 2026-11-02, checked 2026-11-19) lists no GRAS notice for Akkermansia.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have overweight, prediabetes or metabolic syndrome and want a pasteurized product at a studied dose to try for 3 to 4 months alongside diet, exercise and your usual care
You recently lost weight and want an option that, in one trial, reduced weight regain

Probably skip if…

You expect it to replace diabetes or weight-loss medicine; trials showed small effects and the largest missed its main goal
You are pregnant or breastfeeding, or buying for a child under 12, since safety has not been established
You are buying a live product based on results from pasteurized trials, or the reverse

Evidence at a glance

insulin sensitivity

Limited Evidence
Effect
About 29 percent better insulin sensitivity in a 32-person pilot; no difference in the main measure of a 142-person trial
Best fit
Adults with prediabetes or insulin resistance and low gut Akkermansia
Time
3 to 4 months

weight regain after dieting

Limited Evidence
Effect
About 2 kg less weight regain over 24 weeks than placebo
Best fit
Adults who have just lost weight on a diet
Time
24 weeks

blood sugar in type 2 diabetes (live multi-strain product)

Limited Evidence
Effect
HbA1c 0.6 points lower than placebo; borderline effect on after-meal glucose
Best fit
Adults with type 2 diabetes on usual care
Time
12 weeks

weight and HbA1c in type 2 diabetes (live single strain)

Limited Evidence
Effect
No difference from placebo overall
Best fit
Possibly people with low gut Akkermansia (subgroup finding)
Time
12 weeks

muscle strength in older adults

Limited Evidence
Effect
Statistically significant gain in leg extensor peak torque versus placebo
Best fit
Adults aged 60 and over
Time
12 weeks

Evidence for 5 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

insulin sensitivity

Biomarker support
Limited Evidence

In a 3-month pilot trial in 32 overweight or obese adults with insulin resistance who completed it (40 enrolled), 10 billion Akkermansia cells a day, either live or pasteurized, were safe and well tolerated. Compared with placebo, the pasteurized form improved insulin sensitivity by about 29 percent, lowered blood insulin by about 34 percent and total cholesterol by about 9 percent; the abstract reports these gains for the pasteurized form. A larger 4-month trial in 142 adults with metabolic syndrome in Ireland and Germany gave 30 billion pasteurized cells a day and did not improve its main measure, whole-body insulin sensitivity, compared with placebo. Improvements appeared only in exploratory subgroups, mainly people with low Akkermansia levels at the start. Authors of both trials hold patents on Akkermansia or co-founded or work for A-Mansia Biotech or The Akkermansia Company, which develop the pasteurized product.

Effect size
About 29 percent better insulin sensitivity in a 32-person pilot; no difference in the main measure of a 142-person trial
Time to effect
3 to 4 months
Best fit
Adults with prediabetes or insulin resistance and low gut Akkermansia
Less likely
People who already have plenty of Akkermansia in their gut

Bottom line: Promising in a small pilot, not confirmed by the larger trial's main result.

Evidence is mixed

The 142-person trial found no difference from placebo in its primary insulin sensitivity measure; benefits were seen only in exploratory subgroups.

weight regain after dieting

Supplement benefit
Limited Evidence

In a 2026 trial, 90 adults with overweight or obesity first lost at least 8 percent of their weight on an 8-week low-calorie diet, then took pasteurized Akkermansia (strain MucT) or placebo for 24 weeks on a healthy diet. Weight regain was 1.2 kg with Akkermansia and 3.2 kg with placebo. How much Akkermansia people had at the start was linked with how their heart and metabolic markers responded, and no serious treatment-related side effects were seen. The company's co-founder and other company staff were among the authors and inventors on a related patent. This is one trial and needs confirming.

Effect size
About 2 kg less weight regain over 24 weeks than placebo
Time to effect
24 weeks
Best fit
Adults who have just lost weight on a diet
Less likely
People looking for weight loss without diet change

Bottom line: One trial found modestly less weight regain after a diet.

blood sugar in type 2 diabetes (live multi-strain product)

Biomarker support
Limited Evidence

A 12-week trial in 76 adults with type 2 diabetes tested a live multi-strain product (WBF-011) containing Akkermansia muciniphila with four other bacteria and inulin fiber, taken twice a day. Compared with placebo, it lowered total blood sugar over 180 minutes after a standard test meal (glucose area under the curve, minus 36.1 mg/dL per 180 minutes), just reaching statistical significance, and lowered HbA1c by 0.6 points, a secondary outcome. Because the product contained several bacteria and fiber, the effect cannot be credited to Akkermansia alone. All authors were employees and shareholders of the company that makes the product.

Effect size
HbA1c 0.6 points lower than placebo; borderline effect on after-meal glucose
Time to effect
12 weeks
Best fit
Adults with type 2 diabetes on usual care
Less likely
People expecting single-strain Akkermansia products to give the same result

Bottom line: A small company trial of a mixed product; not a replacement for diabetes treatment.

weight and HbA1c in type 2 diabetes (live single strain)

No benefit found
Limited Evidence

In a 12-week Chinese trial in 58 adults with overweight or obesity and type 2 diabetes, a live Akkermansia strain (AKK-WST01, given as live bacteria according to the trial registry) plus lifestyle advice did not lower body weight or HbA1c more than placebo plus the same advice; both groups improved. People with low Akkermansia at the start were colonized well and lost weight, fat and HbA1c, while people with high starting levels were poorly colonized and did not improve. The authors declared no competing interests.

Effect size
No difference from placebo overall
Time to effect
12 weeks
Best fit
Possibly people with low gut Akkermansia (subgroup finding)
Less likely
People with high gut Akkermansia

Bottom line: Overall, no better than placebo; any benefit may be limited to people low in Akkermansia.

muscle strength in older adults

Supplement benefit
Limited Evidence

In a 12-week Korean trial in 100 adults aged 60 and over, a pasteurized Akkermansia strain from a different company (HB05, 10 billion cells a day) improved peak strength of the left leg extensor muscles more than placebo and raised follistatin, a protein that counteracts the muscle-limiting protein myostatin. No safety concerns were reported. Some authors were employees of the company that makes the strain. Hand grip strength did not change. This is one trial with a laboratory strength measure.

Effect size
Statistically significant gain in leg extensor peak torque versus placebo
Time to effect
12 weeks
Best fit
Adults aged 60 and over
Less likely
Younger, active adults

Bottom line: One small trial; strength training remains the proven approach.

How it works

Population studies have found less Akkermansia in the gut of people with obesity, untreated type 2 diabetes or high blood pressure. In preclinical research, giving the bacterium protected against diet-induced weight gain, and the pasteurized form improved gut barrier function, which suggests that parts of the bacterial cell, not live growth, may drive at least some effects. In human trials, starting Akkermansia levels have been linked with how people respond. With a live strain, low-baseline participants were colonized well and improved, while high-baseline participants were poorly colonized and did not. This means average results can hide large differences between people, and it is not yet practical to know your own level without a stool test.

How to take it

1. Typical dose
Studied doses: 10 billion cells per day of live or pasteurized Akkermansia for 3 months (overweight adults with insulin resistance), and 30 billion pasteurized cells per day for 4 months (adults with metabolic syndrome). There is no established dose.
2. Higher studied dose
The highest daily amount in the trials above was 30 billion pasteurized cells. EFSA judged up to 34 billion cells a day safe for adults; that is a safety limit, not a dose shown to work
3. Timing
In the weight-maintenance trial, the pasteurized product was taken in water at least 15 minutes before breakfast (as described in the trial registry)
4. With food
Before breakfast in one trial; not compared in others
5. Split dosing
Once daily in the trials
6. How long to try
3 to 6 months in trials

What to track

Weight and waist size
Fasting blood sugar or HbA1c if you have prediabetes or diabetes
Digestive symptoms in the first weeks

Bottom line: Choose the form that was actually studied (most data are for pasteurized), at a studied dose, and judge it after about 3 months.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Trials of live and pasteurized forms for 3 to 6 months reported them as safe and well tolerated, with no serious treatment-related adverse events

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Not established. EFSA's 2021 safety review covered adults excluding pregnant and breastfeeding women, and its 2025 review found no evidence provided for safety in pregnancy and breastfeeding. Talk with your doctor before using any Akkermansia product while pregnant or breastfeeding.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Form clearly stated: pasteurized (heat-killed) or live
Cell count per daily dose (pasteurized trials used 10 billion to 30 billion cells a day)
Strain named (for example MucT), so you can match the product to a trial
For live products: storage instructions and a count guaranteed until the expiry date, not only at manufacture

Be skeptical of…

"Works like a GLP-1 weight-loss drug" (one trial found a rise in GLP-1 after a glucose drink; weight effects were small)
"Reverses diabetes" or "replaces your diabetes medicine"
"Heals leaky gut" (the barrier effect was shown in preclinical models)
Results from pasteurized trials used to sell a live product, or the reverse

Frequently asked questions

Should I choose live or pasteurized Akkermansia?⌄

Most of the published trials, including the weight-regain and metabolic syndrome trials, used pasteurized Akkermansia. In the 2019 pilot trial, the metabolic improvements reported in the abstract were for the pasteurized form. Live forms have been tested in fewer trials, one of them as part of a multi-strain mix. Check that the form and strain on the label match a trial.

Will Akkermansia help me lose weight?⌄

Not by much on its own. In one trial, people who had just lost weight on a diet regained about 2 kg less over 24 weeks with pasteurized Akkermansia than with placebo. In people with type 2 diabetes, a live strain did not reduce weight more than placebo overall.

Is Akkermansia approved?⌄

In the EU, the food safety agency EFSA judged pasteurized Akkermansia safe as a novel food at up to 34 billion cells a day for adults (2021), and in 2025 for teenagers from 12 at lower amounts (up to 21 billion cells a day at ages 12 to 13 and 30 billion at ages 14 to 17). The FDA's GRAS Notice Inventory (last updated 2026-11-02) lists no GRAS notice for Akkermansia. In the US, supplements do not need FDA approval before they are sold.

Can I take Akkermansia with my medicines or other supplements?⌄

No interaction studies have been published. Trials in people with type 2 diabetes did not report interaction problems, but none was designed to study interactions. Ask your doctor or pharmacist to check your own list, especially if you take diabetes medicines, since a change in blood sugar would matter.

Why did it work for some people and not others?⌄

Several trials found that people with little Akkermansia in their gut at the start improved, while people with plenty did not. Your starting level can only be measured with a stool test.

References by claim

insulin sensitivity

Depommier et al., 2019 · PMC (2019) link

Suenaert et al., 2026 · PMC (2026) link

weight regain after dieting

Mount et al., 2026 · PubMed (2026) link

blood sugar in type 2 diabetes (live multi-strain product)

Perraudeau et al., 2020 · PMC (2020) link

weight and HbA1c in type 2 diabetes (live single strain)

Zhang et al., 2025 · PubMed (2025) link

muscle strength in older adults

Kang et al., 2024 · PMC (2024) link

Safety

Turck et al., 2025 · PMC (2025) link

Turck et al., 2021 · PMC (2021) link

Track Akkermansia with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments. Talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.